MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Full Archive

The full archive of mesothelioma-related journal articles. All articles belong to this category.

Malignant mesothelioma cells secrete natriuretic peptides: Data and diagnostic clinical implications.

Respirology 2020 March 2 [Link] Tsolaki V, Zarogiannis S, Zygoulis P, Kalomenidis I, Jagirdar R, Makris D, Daniil Z, Magkouta S, Triantafyllou I, Papanikolaou J, Gourgoulianis KI, Zakynthinos E Abstract BACKGROUND AND OBJECTIVE: Mesothelial cells and cardiomyocytes have shared embryonic mesodermal origin. Cardiomyocytes release BNP under stretch. We searched whether malignant mesothelioma cells also secrete […]

March 16, 2020

Biphasic or Mixed, Epithelioid, Full Archive, Pleural, Sarcomatoid
Comments Off on Malignant mesothelioma cells secrete natriuretic peptides: Data and diagnostic clinical implications.

Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.

The Journal of Thoracic and Cardiovascular Surgery 2020 January 30 [Link] De León LE, Bravo-Iñiguez CE, Fox S, Tarascio J, Freyaldenhoven S, Lapidot M, Jaklitsch MT, Bueno R Abstract OBJECTIVE: The purpose of this study was to determine the incidence of venous thromboembolism and utility of a routine surveillance program in patients undergoing surgery for […]

March 13, 2020

Full Archive, Pleural, Pleurectomy/decortication
Comments Off on Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.

A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Lung Cancer 2020 February 12 [Link] Zucali PA, Perrino M, De Vincenzo F, Giordano L, Cordua N, D’Antonio F, Santoro A Abstract OBJECTIVES: Second-line chemotherapy is not a standard of care in patients with malignant pleural mesothelioma (MPM) that progresses after first-line treatment with cisplatin and pemetrexed. In pre-clinical models, the combination of gemcitabine (GEM) […]

March 12, 2020

Cisplatin (Platinol ®), Full Archive, Immunohistochemistry or IHC, Pemetrexed (Alimta), Pleural
Comments Off on A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.

Journal of Immunotherapy for Cancer 2020 February [Link] Hotta K, Fujimoto N Abstract Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both […]

March 11, 2020

Biomarkers, Chemotherapy, Full Archive, Pleural
Comments Off on Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.

The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.

Clinical Radiology 2020 February 18 [Link] Sinha S, Swift AJ, Kamil MA, Matthews S, Bull MJ, Fisher P, De Fonseka D, Saha S, Edwards JG, Johns CS Abstract Malignant pleural mesothelioma (MPM) is a primary malignancy of the pleura and is associated with a poor outcome. The symptoms and signs of malignant mesothelioma present late […]

March 6, 2020

Full Archive, Occupational Asbestos Exposure, Pleural
Comments Off on The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.

Genetic alterations of malignant pleural mesothelioma: association to tumor heterogeneity and overall survival.

Molecular Oncology 2020 February 21 [Link] Quetel L, Meiller C, Assié JB, Blum Y, Imbeaud S, Montagne F, Tranchant R, de Wolf J, Caruso S, Copin MC, Hofman V, Gibault L, Badoual C, Pintilie E, Hofman P, Monnet I, Scherpereel A, Le Pimpec-Barthes F1, Zucman-Rossi J, Jaurand MC, Jean D Abstract Development of precision medicine […]

March 5, 2020

Epithelioid, Full Archive, Pleural, Sarcomatoid
Comments Off on Genetic alterations of malignant pleural mesothelioma: association to tumor heterogeneity and overall survival.

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

Annals of Oncology 2020 January 16 [Link] Metaxas Y, Früh M, Eboulet EI, Grosso F, Pless M, Zucali PA, Ceresoli GL, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R; Swiss Group for Clinical Cancer Research (SAKK). Abstract BACKGROUND: Systemic second- […]

March 4, 2020

Biphasic or Mixed, Chemotherapy, Epithelioid, Full Archive, Immune-based Therapies, Pemetrexed (Alimta), Pleural, Sarcomatoid
Comments Off on Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

Disease-Related Outcomes and Toxicities of Intensity-Modulated Radiation Therapy Following Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.

Practical Radiation Oncology 2020 February 20 [Link] Patel R, Ludmir EB, Miccio JA, Menon H, Barsky AR, Mesko SM, Kodali M, Lautenschlaeger T, Adeberg S, Simone CB 2nd, Verma V Abstract PURPOSE: To explore the use of intensity-modulated radiotherapy (IMRT) after lung-sparing surgery in malignant pleural mesothelioma (MPM). Because severe toxicities have been documented following […]

March 3, 2020

Full Archive, Pleural, Pleurectomy/decortication, Radiotherapy
Comments Off on Disease-Related Outcomes and Toxicities of Intensity-Modulated Radiation Therapy Following Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.

Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.

Lung Cancer 2020 February 14 [Link] Bronte G, Delmonte A, Burgio MA, Verlicchi A, Puccetti M, Bravaccini S, Cravero P, Tumedei MM, Diano D, Rossi G, Ulivi P, Martinelli G, Crinò L Abstract OBJECTIVES: Treatment options for malignant pleural mesothelioma (MPM) are limited but some studies on immune checkpoint inhibitors (ICIs) in MPM have reported […]

March 2, 2020

Carboplatin, Cisplatin (Platinol ®), Epithelioid, Full Archive, Gemcitabine (Gemzar), Pemetrexed (Alimta), Pleural, Pleural Effusion, Pleurectomy/decortication
Comments Off on Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.

An in vivo immunohistochemical study on MacroH2A.1 in lung and lymph-node tissues exposed to an asbestiform fiber.

Current Molecular Science 2020 February 20 [Link] Loreto C, Lombardo C, Caltabiano R, Ledda C, Hagnas M, Filetti V, Rapisarda V Abstract AIMS: The aim of this study was to investigate MacroH2A.1 immunoexpression in tissues of sheep exposed to FE. BACKGROUND: The correlation between asbestiform fibers, lung cancer, pleural mesothelioma and other lung diseases is […]

February 28, 2020

Full Archive, Immunohistochemistry or IHC, Pleural
Comments Off on An in vivo immunohistochemical study on MacroH2A.1 in lung and lymph-node tissues exposed to an asbestiform fiber.